Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of MEDI9090 With Durvalumab in Advanced Solid Tumors
jRCT2080223391Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2016
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of MEDI9090 and durvalumab in Nonhematologic neoplasms, sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of MEDI9090 in combination with durvalumab and Pharmacokinetics of MEDI9090. Started Nov 2016; status: completed.
02
Drugs
MEDI9090durvalumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080223391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223391.